Company / SG&A Expense
GT Biopharma, Inc. SG&A Expense History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$9.8M
FY2020
5-year range
$935.0K / $9.8M
FY2016-FY2020
Trend
+16.6%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 4 consecutive years, from $935,000 in FY2014 to $10M in FY2020.
Based on SEC 10-K filings.
$10M in FY2020 with a 5-year CAGR of +32.5%.
Increased from $8M to $10M over the past 4 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +5.2%
- 5-Year CAGR
- +32.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- GT Biopharma, Inc.'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +32.5%, indicating consistent growth.
- In FY2020, sg&a expense increased 16.6% year-over-year.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $9.8M | +16.6% |
| FY2017 | $8.4M | +5.6% |
| FY2016 | $8.0M | +231.4% |
| FY2015 | $2.4M | +156.7% |
| FY2014 | $935.0K | -72.2% |
| FY2013 | $3.4M | -3.1% |
| FY2012 | $3.5M | +53.2% |
| FY2011 | $2.3M | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026